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Biomarker discoveryAbstract Background: Dose-dense administration of chemotherapy and the addition of tax-
anes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival sub-
stantially. However, clinical trials directly comparing the additive value of taxanes with dose-
dense anthracycline-based chemotherapy are lacking.
Patients and methods: In the multicentre, randomised, biomarker discovery Microarray Anal-
ysis in breast cancer to Tailor Adjuvant Drugs Or Regimens (MATADOR) trial, patients with
pT1-3, pN0-3 breast cancer were randomised (1:1) between six adjuvant cycles of doxorubicin
60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC) and six cycles of docetaxel
75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC). The
primary objective was to discover a predictive gene expression profile for ddAC and TAC
benefit. Here we report the preplanned secondary end-point recurrence-free survival (RFS)
and overall survival (OS).
Results: Between 2004 and 2012, 664 patients were randomised. At 5 years, RFS was 87%
(95% confidence interval [CI] 83%e91%) in the ddAC-treated patients and 88% (84e92%)
in the TAC-treated subgroup (hazard ratio [HR] 0.89, 95% CI 0.62e1.28, P Z 0.53). OS at
5 years was 93% (90%e96%) in the ddAC-treated and 94% (91%e97%) in the TAC-treated
patients (HR 0.89, 95% CI 0.57e1.39, P Z 0.61). Anaemia was more frequent in ddAC-
treated patients (62/327 patients [18.9%] versus 15/319 patients [4.7%], P < 0.001) and diar-
rhoea (21 [6.4%] versus 53 [16.6%], P<0.001) and peripheral neuropathy (15 [4.6%] versus
46 [14.4%], P < 0.001) were observed more often in TAC-treated patients.
Conclusions: With a median follow-up of 7 years, no significant differences in RFS and OS
were observed between six adjuvant cycles of ddAC and TAC in high-risk breast cancer pa-
tients.
Trial registration numbers: ISRCTN61893718 and BOOG 2004-04.
ª 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adjuvant chemotherapy for early breast cancer aims to
eradicate micrometastases to improve survival.
Anthracycline-containing regimens have increased
breast cancer survival substantially [1].
Incorporation of taxanes into anthracycline-based
schedules has further improved the efficacy of adjuvant
chemotherapy. Compared with six cycles of 5-
fluorouracil-doxorubicin-cyclophosphamide, six cycles
of adjuvant docetaxel-doxorubicin-cyclophosphamide
(TAC) significantly improved overall survival (OS) from
81% to 87% in node-positive breast cancer [2]. The addi-
tion of four cycles of a taxane to a fixed anthracycline-
based regimen, thereby extending treatment duration,
also improved breast cancerespecific survival (BCSS) [1].
Dose-dense scheduling of chemotherapeutic agents
accounted for another important step forward. Dose
densification is defined as the shortening of the interval
between cycles, giving the tumour less time to regrow
between treatment cycles. Three meta-analyses showed
that adjuvant dose-dense chemotherapy improves dis-
ease-free survival (DFS) and OS of breast cancer pa-
tients compared with conventionally scheduled
chemotherapy regimens [3e5].
Knowing that both the addition of a taxane and dose-
dense scheduling increase efficacy of adjuvant chemo-
therapy, it is unclear which of these strategies gives the
largest benefit for an individual patient. Two studiescompared a taxane-based, dose-dense regimen directly
with conventional dosed anthracycline-based treatment,
resulting in a minor survival advantage for dose-den-
seetreated patients compared with conventionally
treated patients [6,7]. However, to date, no randomised
trial has directly compared a taxane-containing,
conventionally scheduled treatment with a non-tax-
aneecontaining, dose-dense regimen. Here, we report
the results of the preplanned secondary analyses of a
randomised, biomarker discovery trial comparing six
cycles of dose-denseeadministered AC (ddAC) with six
cycles of adjuvant TAC. The primary objective of this
trial was to investigate whether a gene expression profile
could be identified that could predict who should receive
ddAC and who should receive TAC for the best
outcome. Application of such a classifier would then
lead to a better outcome for the whole group, than when
all patients would have received one of these regimens
that would have turned out best for the average patients.
2. Materials and methods
2.1. Study design and patients
The Microarray Analysis in breast cancer to Tailor
Adjuvant Drugs Or Regimens (MATADOR,
ISRCTN61893718) study is a multicentre, randomised,
open-label, phase III trial primarily designed to identify
a gene expression profile that can predict survival benefit
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confirmed T1-T3, N0-3b adenocarcinoma of the breast
without signs of distant metastases were considered
eligible. The study was amended to also include N0
patients from June 2008 onwards (Amendment 2).
Adequate bone marrow, liver and renal functions were
required. Main exclusion criteria were prior systemic
treatment for cancer, history of breast cancer and other
cancers (except for curatively treated non-melanoma
skin cancer, in situ carcinoma of the cervix and ipsilat-
eral ductal carcinoma in situ) and significant cardiac,
neurological or psychiatric disorders. With trastuzumab
not being part of the study treatment and accumulating
evidence showing that concurrent trastuzumab and
chemotherapy appeared superior compared with
sequential scheduling, patients with human epidermal
growth factor receptor (HER2)epositive disease were
considered ineligible after 2007 (Amendment 2).
The study protocol and amendments were approved
by the ethical committee of the Netherlands Cancer
Institute and the institutional review boards of the
participating centres. The study was performed in
accordance with Good Clinical Practice guidelines and
with the Declaration of Helsinki (version 17C). All pa-
tients provided written informed consent.
2.2. Randomisation and treatment
Patients were initially randomised among four treat-
ments: four or six cycles of ddAC or four or six cycles of
TAC. With emerging evidence that six cycles of fluoro-
uracil-doxorubicin-cyclophosphamide (FAC) resulted in
better outcomes than six cycles of cyclophosphamide-
methotrexate-fluorouracil (CMF) [8], with six cycles of
CMF being equally effective as four cycles of AC [9],
randomisation was limited to the six cycle regimen
(Amendment 1). By then, five patients had received four
cycles of ddAC and five patients received four cycles of
TAC. Randomisation (1:1) was performed centrally at
the Netherlands Cancer Institute using the automated
ALEA system (FormsVision BV, the Netherlands).
Patient received either six cycles of doxorubicin
60 mg/m2 plus cyclophosphamide 600 mg/m2 every 2
weeks or six cycles of docetaxel 75 mg/m2, doxorubicin
50 mg/m2 and cyclophosphamide 500 mg/m2 every 3
weeks. Granulocyte colonyestimulating factor (pegfil-
grastim 6 mg) was given to all patients the day after
chemotherapy administration. Prophylactic antibiotics
were not standard of care in the study.
Randomisation was stratified by the menopausal
status, type of surgery, sequence of adjuvant therapy,
tumour size and lymph node status according to AJCC
staging, hormone receptor status, HER2 status and
treatment centre using Pocock’s minimisation technique.
Dose reductions and interruptions were allowed in
case of adverse events grade III or higher according to
common toxicity criteria for adverse events (CTCAE),version 3.0, except for peripheral neuropathy that
required dose reduction of docetaxel at grade II. Adju-
vant radiotherapy and/or endocrine therapy were initi-
ated according to the Dutch guidelines on breast cancer
treatment (www.oncoline.nl).
2.3. Assessments
Patients were assessed for relapse of disease at regular
intervals for 10 years. Evaluation included physical ex-
amination and yearly mammography. Adverse events
grade II andhigherwere reported using theCTCAE, v3.0.
Histological grade according to the modified Bloom-
Richardson classification [10] and morphology were
assessed locally. Tissue microarrays (3 cores of 0.6 mm
per patient) were constructed and stained for oestrogen
receptor (ER), progesterone receptor (PR) and HER2.
According to the Dutch guidelines, ER and PR staining
of 10% or more and HER2 score of 3 þ or more were
scored as positive. In case of a 2 þ HER2 score, an in
situ hybridisation assay was performed. Central assess-
ment of ER, PR and HER2 was used. If tumour tissue
was unavailable, local assessment was used. Breast
cancer subtype was defined as (1) ER and/or PR positive
and HER2 negative; (2) HER2 positive, regardless of
ER and PR status or (3) triple negative.
2.4. Objectives and end-points
The primary objective of the trial was to generate a gene
expression profile predictive of DFS benefit of either
dose-dense chemotherapy or a docetaxel-containing
schedule. DFS was defined as the interval between
randomisation and locoregional or distant relapse, sec-
ond primary cancer, or death by any cause. Because a
second primary cancer could not directly be attributed
to failure of eradicating micrometastases with systemic
treatment, the study protocol was amended (Amend-
ment 3) to change the primary end-point to recurrence-
free survival (RFS). RFS was defined as the interval
between randomisation and locoregional or distant
relapse or death by any cause [11].
The secondary objective was to compare the efficacy
of TAC and ddAC. End-points included RFS, distant
recurrence-free interval (DRFI), defined as the time
from randomisation until distant relapse or breast
cancererelated death, OS and BCSS. Also, we evaluated
the patients who received at least one cycle of the allo-
cated treatment for toxicity during follow-up.
2.5. Statistics
The primary end-point of the trial was the gain in RFS
attributed to the genetic profile. This gain was defined as
the improvement of RFS at 5 years with the treatment
strategy using the profile, over the strategy in which all
patients would get the same treatment (either ddAC or
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comparison (which was the secondary objective). It was
calculated that if the profile would be developed using
data from 400 patients, the standard error of the esti-
mate of the gain would be less than 2.5%. The sample
size of the study was set at 660 so that 1/3 of the data
could be used as a validation cohort, allowing for 10%
early dropout. For the direct comparison of the arms
(the secondary objective), 192 RFS events were required
to obtain 80% power to detect a difference of a hazard
ratio (HR) of 0.67. During the course of the study, it
became clear that the event rate was lower than ex-
pected. Therefore an amendment was made to the pro-
tocol. At the time of this amendment, RFS 87 events
were observed, and it was calculated that with a two-sided
significance level of a Z 0.025 (to account for a final
analysis after 10 years of follow-up), the smallest differ-
ence that could be detected with 80% power was anHRof
approximately 0.50.Results from theEarly BreastCancer
Trialists’ Collaborative Group (EBCTCG) overview [1]
suggested that the benefit of taxanes diminishes after 5
years; so waiting formore events would not providemuch
more information about sensitivity to treatment with
taxanes. Therefore, the analysis after 5-year follow-up
was added to the amendment (Amendment 3). In addi-
tion, it was decided to use a cross-validation method
instead of separation in a development and a validation
cohort as this may result in a better profile and more
precise estimates of its predictive accuracy.
The database was closed on 14 November 2017. We
compared the categorical clinicopathological character-
istics of the two treatment groups using a Chi-square or
Fisher’s exact test.
Efficacy analyses were performed in the intention-to-
treat (ITT) population, including all patients who were
allocated tooneof the two treatmentarms.RFS,DRFI,OS
and BCSS of the two treatments were estimated using the
Kaplan-Meier method and compared with a log-rank test.
Multivariable Cox proportional hazards models were
generated to correct for known prognostic factors.
Exploratory subgroup analyses on RFS and OS, including
interactions, were performed using Cox regression models.
Additionally, efficacy analyses were performed in the
per-protocol treated (PPT) subgroup. The PPT popu-
lation consisted of patients who received at least one
treatment of ddAC or TAC. Patients were excluded if
they were randomised to and received four cycles of
chemotherapy, if they randomised for ddAC and were
treated with an adjuvant taxane outside the scope of this
study or if they had HER2-positive disease.
Observed toxicity was evaluated in all patients who
received at least one cycle of the allocated treatment and
was compared using a Chi-square or Fisher’s exact test.
All p-values were two sided, and values below 0.05
were considered significant, except for the comparison
of ddAC with TAC for the RFS efficacy end-point,
where the threshold was set at 0.025 (two sided).Statistical analyses were performed using SPSS 22 and R
3.3.1.3. Results
Between 2004 and 2012, 664 patients were enrolled and
randomised in 29 centres throughout the Netherlands
(ITT population). Toxicity analysis was performed in
646 patients. The PPT population consisted of 614 pa-
tients (Fig. 1).
The treatment groups were well balanced regarding
prognostic clinicopathologic characteristics (Table 1).
Mean age was 51.1 years (standard deviation, 8.0). Five
hundred thirty-one of 664 patients (80%) had lymph
nodeepositive disease and 108 patients (16.3%) had
triple-negative breast cancer. Twenty-one patients with
HER2-positive disease were included of whom 14 were
treated with trastuzumab.3.1. Efficacy
At the time of the analyses, the ITT population had a
median follow-up of 7 years. Two hundred eighty
(84.3%) of 332 patients completed six cycles ddAC at the
planned dose; 271 (81.6%) of 332 patients received six
full cycles of TAC treatment (PZ0.41).
The estimated 5-year RFS rate was 86.9% (95% CI
83.3e90.6) in the ddAC-treated patients and 87.9%
(84.4e91.5) in the TAC-treated subgroup, which was
not significantly different (HR 0.89, 95% CI 0.62e1.28,
PZ0.53; Fig. 2a), neither after adjustment for known
prognostic factors (Supplementary Table S1). The same
holds true for DRFI (Supplementary Fig. S1 and Table
S2). Of note, although not shown here, similar results
were obtained using DFS as primary end-point.
The 5-year OS did not significantly differ between the
two treatment arms: 92.6% (95% CI 89.8e95.5) in the
ddAC-treated subgroup and 93.8% (91.1e96.5) in the
TAC-treated patients (HR 0.89, 95% CI 0.57e1.39,
PZ0.61; Fig. 2b), neither when adjusted for known
prognostic factors (Supplementary Table S3). No dif-
ference was observed for BCSS between ddAC and TAC
(Supplementary Fig. S2 and Table S4).
In the exploratory subgroup analyses, the interaction
between age as a dichotomous variable and treatment
showed a trend for OS (PinteractionZ 0.040; Fig. 3) with
a numerical survival benefit for patients younger than 50
years when treated with ddAC (HR 1.72, 95% CI
0.79e3.73) and for patients who were 50 years or older
when treated with TAC (HR 0.62, 95% CI 0.35e1.11).
The interaction was not significant for RFS
(Pinteraction Z 0.084; Supplementary Fig. S3).
Fifty patients were excluded from the PPT analyses
(Fig. 1). Similar to the ITT population, RFS and OS
were not significantly different between the ddAC- and
the TAC-treated patients (Supplementary Fig. S4a-b).
Fig. 1. CONSORT diagram. A, doxorubicine; C, cyclophosphamide; T, docetaxel; dd, dose-dense; HER2, human epidermal growth factor
receptor 2; ITT, intention-to-treat; PPT, per-protocol treated.
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The observed adverse events (grade II and higher) of the
two treatments are distinct (Table 2). Importantly,
anaemia was more frequent in ddAC-treated patients (62
[18.9%] of 327 patients versus 15 [4.7%] of 319 patients,
P<0.001) and diarrhoea (21 [6.4%] versus 53 [16.6%],
P<0.001) and peripheral neuropathy (15 [4.6%] versus 46
[14.4%], P<0.001) were observed more often in TAC-
treated patients. Regarding severe adverse events, acute
myeloid leukaemia (AML) occurred twice in both treat-
ment groups. One ddAC-treated patient developed mye-
lodysplastic syndrome (MDS). Cardiac failure grade III
or IV was observed in one ddAC-treated patient and in
two TAC-treated patients. Toxicity of ddAC and TAC
treatment in the context of drug metabolismerelated
polymorphisms was reported elsewhere [12].
4. Discussion
Here we present the first direct comparison of efficacy of
six cycles of ddAC and six cycles of TAC as adjuvanttreatment for breast cancer as a secondary analysis of a
randomised biomarker discovery trial. With a median
follow-up of 7 years, ddAC and TAC were not signifi-
cantly different regarding the survival end-points in our
study. This is in line with the Oxford Overview meta-
analysis [1] that contains more than 14,000 patients for
the specific comparison between taxanes given concur-
rently with anthracyclines versus a non-tax-
aneecontaining regimen with a less than two times
increased dose of non-taxane chemotherapy and with the
CALGB40101 trial [13]. Interestingly when compared
with the previously mentioned meta-analysis data, the
survival rates in our cohort were remarkably high,
particularly in this high-risk patient population in which
80.0% of the patients had lymph nodeepositive disease.
Several factors might have contributed to the rela-
tively high survival rates of our cohort compared with
previously reported outcomes in older studies. First,
patients with HER2-positive disease were excluded after
the introduction of trastuzumab. In older cohorts that
included the HER2-positive tumours that were not
treated with anti-HER2ebased therapy, the survival
Table 1
Baseline characteristics of intention-to-treat population.
Clinicopathologic characteristic 6 ddAC, N Z 332 6 TAC, N Z 332 p-value
Age groups (%) <50 years 143 (43.1) 154 (46.4) 0.435
50 years 189 (56.9) 178 (53.6)
Surgery (%) Breast-conserving surgery 180 (54.2) 169 (50.9) 0.538
Mastectomy 151 (45.5) 158 (47.6)
Missing 1 (0.3) 5 (1.5)
Endocrine treatment (%) No 54 (16.3) 59 (17.8) 0.641
Yes 278 (83.7) 268 (80.7)
Missing 0 (0) 5 (1.5)
T stageb (%) T1 158 (47.6) 155 (46.7) 0.654a
T2 156 (47.0) 152 (45.8)
T3 16 (4.8) 19 (5.7)
T4 2 (0.6) 0 (0)
Missing 0 (0) 6 (1.8)
N stageb (%) N0 65 (19.6) 63 (19.0) 0.889
N1 208 (62.7) 200 (60.2)
N2 44 (13.3) 45 (13.6)
N3 15 (4.5) 19 (5.7)
Missing 0 (0) 5 (1.5)
Gradec (%) Good 32 (9.6) 35 (10.5) 0.796
Intermediate 151 (45.5) 138 (41.6)
Poor 139 (41.9) 137 (41.3)
Missing 10 (3.0) 22 (6.6)
Histology (%) Ductal 270 (81.3) 257 (77.4) 0.507
Lobular 47 (14.2) 46 (13.9)
Other 13 (3.9) 19 (5.7)
Missing 2 (0.6) 10 (3.0)
Subtyped (%) ER and/or PR positive, HER2 negative 266 (80.1) 269 (81.0) 0.800
HER2 positive 12 (3.6) 9 (2.7)
Triple negative 54 (16.3) 54 (16.3)
A, doxorubicin; C, cyclophosphamide; T, docetaxel; dd, dose-dense.
a Pearson Chi-square test or Fisher’s exact test (two sided), missing values excluded.
b According to AJCC staging 6th edition.
c Grading according to the modified Bloom-Richardson grading system.
d ER and PR nucleic staining of 10% staining or more was scored as positive and HER2 score of 3 þ was considered positive; in case of a
2 þHER2 score, an in situ hybridisation assay was performed; subtypes were defined as (1) oestrogen receptor (ER) and/or progesterone receptor
(PR) positive, human epidermal growth factor receptor 2 (HER2) negative; (2) HER2 positive, regardless of ER or PR status; (3) triple (ER, PR,
HER2) negative.
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known as the Will Rogers phenomenon, might play a
role. Improved diagnostics and new technologies, as
shown previously for 18F-fluorodeoxyglucose positron
emission tomography combined with computed to-
mography [16], lead to more accurate identification of
(distant) metastases. Patients who would have been
diagnosed with stage III disease in the past and treated
with adjuvant systemic therapy are nowadays diagnosed
with stage IV disease [17]. The taxane plus anthracycline
trials reported in the Oxford Overview meta-analysis
enrolled patients between 1994 and 2005, almost a
decade earlier than inclusion of patients in the current
trial (2004e2012). Interestingly, the MINDACT trial
(2007e2011) was executed in the same time period in
Europe, and our relatively favourable survival data
resemble the survival data of the high-risk patients
included in MINDACT who received adjuvant chemo-
therapy [18].The primary objective of this trial is to generate a
predictive gene expression profile, which is currently
being explored. Because the sample size was calculated
for the primary end-point, the study may be under-
powered for the secondary objective, particularly with
the unexpected low number of events observed. How-
ever, because chemotherapy displays the largest survival
effect in the first years after diagnosis and the carry-over
effect diminishes after 7 years for taxanes and even
earlier for anthracycline-based regimens [1], it seems
relevant to report these results now.
The enrolment period from 2004 until 2012 was
relatively long. The novel design of a biomarker study
required some adjustments of daily clinical practice. To
ensure sufficient quality of the RNA, the ability to
freeze tumours was a requirement for hospitals to
participate in the trial. At the start of this trial, only a
few hospitals had the logistics in place to freeze tumours
after surgery. Given the speedy accrual of other
Fig. 2. Recurrence-free survival (a) and overall survival (b) of the
intention-to-treat population. A, doxorubicine; C, cyclophospha-
mide; T, docetaxel; dd, dose-dense; HR, hazard ratio; CI, confi-
dence interval.
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later, such as but not limited to the MINDACT trial,
developments in molecular diagnostics have resulted in
logistics for frozen tumours in the majority of hospitals
nowadays. Also, emerging evidence caused a shifting
landscape of potential adjuvant systemic treatment
regimens, compromising the accrual. Nevertheless, the
primary objective of this trial is still a valid and clini-
cally relevant aim.
In this trial, we evaluated three variables: (1) the time
between cycles (2 weeks versus 3 weeks), (2) the differentdosages of doxorubicin (60 mg/m2 versus 50 mg/m2) and
cyclophosphamide (600 mg/m2 versus 500 mg/m2) and
(3) the taxane addition. The number of variables makes
it difficult to assess to what extent a specific factor
contributes to the efficacy of these regimens. The lack of
superiority of TAC over ddAC could be due to the
somewhat higher dosed doxorubicin and cyclophos-
phamide in the ddAC arm compared with TAC, thereby
increasing the dose intensity defined as mg/m2 per time
interval. The dose-dense schedule further increases the
dose intensity without increasing the toxicity [19]. Dose
intensification of doxorubicin and cyclophosphamide
seems, therefore, equally effective as the addition of
docetaxel to these agents after a median follow-up of 7
years in our cohort.
The unplanned subgroup analysis provided some
evidence of an interaction between age and treatment,
with a numerical OS benefit for younger patients (<50
years) when treated with ddAC compared with TAC
and for older patients (50 years) when treated with
TAC compared with ddAC. These results are in line
with a previous report on improved survival after dose-
dense chemotherapy compared with standard-interval
chemotherapy in young breast cancer patients [20]. Also,
higher survival rates are observed in older patients
treated with taxane-containing regimens compared with
patients of the same age treated with non-taxaneebased
regimens [1,21]. Although one might expect ddAC to be
more efficacious in relative aggressive tumours that are
more prevalent in younger patients [19,22], we did not
observe an association between the grade and age in our
population, nor did we find a significant interaction
between the grade and treatment effect. Currently
ongoing gene expression analyses might provide hints on
the biology that could be driving this.
The regimens used in our cohort displayed distinct
toxicity profiles, which are in line with previous studies on
dose-dense chemotherapy [4,13] and reports on taxane-
based treatments [23,24]. AML and MDS were observed
in 2 (0.6%) of 327 ddAC-treated patients and 2 (0.6%) of
319 TAC-treated patients. Previous anthracycline-based
studies have shown a similar probability of AML and
MDSof 0.55% at 8 years of follow-up [25]. Comparedwith
theBCIRG001 trial [24], cardiac failurewas uncommon in
our study population (1 ddAC-treated patient [0.3%], 2
TAC-treated patients [0.6%]). However, longer follow-up
is needed to assess the long-term toxicity of these regimens.
Because these toxicities are associated with anthracyclines
in a dose-dependent manner, four courses of
anthracycline-based chemotherapy, followed by taxanes
may be the preferred regimen in the absence of predictive
biomarkers for regimen-specific efficacy. Predicting sensi-
tivity for toxicity, for instance by screening for genetic
polymorphisms, may help to tailor treatment [12,26]. In
addition, treatment duration might be important for some
patients. For these patients, a 12-week during schedule
might bemore attractive than an 18-week during schedule.
Table 2
Most frequent toxicities (grade II or higher) for ddAC-treated patients
and TAC-treated subgroup.
Side-effects ddAC, n Z 327 (%) TAC, n Z 319 p-valuea
Anaemia 62 (18.9) 15 (4.7) <0.001
Leukocytopenia 30 (9.2) 20 (6.3) 0.167
Fatigue 117 (35.8) 109 (34.2) 0.668
Diarrhoea 21 (6.4) 53 (16.6) <0.001
Nausea 65 (20.0) 52 (16.3) 0.238
Vomiting 35 (10.7) 21 (6.6) 0.063
Febrile neutropenia 36 (11.0) 40 (12.5) 0.546
Peripheral
neuropathy
15 (4.6) 46 (14.4) <0.001
A, doxorubicin; C, cyclophosphamide; T, docetaxel dd, dose-dense.
The p-values printed in bold are below a significance level of 0.05.
a Pearson Chi-square test (two-sided).
Fig. 3. Forest plot of treatment effect on overall survival in subgroups. T stage and N stage are based on the TNM classification 2002. A,
doxorubicin; C, cyclophosphamide; T, docetaxel; dd, dose-dense; HR, hazard ratio; CI, confidence interval; ER, oestrogen receptor; PR,
progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, . Subtypes were defined as (1) ER and/or PR positive,
HER2 negative and (2) triple (ER, PR, HER2) negative.
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Our data show that the 5-year survival of high-risk
breast cancer patients is excellent after adjuvant treat-
ment with six cycles of TAC or six cycles of ddAC and
that distinct toxicity profiles and treatment durations
characterise these schedules. Although the preferred
adjuvant schedule may shift towards dose-dense
sequential chemotherapy [5], knowledge about ‘second
best’ schedules with their own characteristics may help
to search for alternative regimens if required. In addi-
tion, predictive biomarkers are warranted to further
improve well-informed treatment decisions. Therefore,
we aim to develop a gene expression profile predictive
for treatment efficacy of either ddAC or TAC.Role of the funding sources
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